Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

851
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
851
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

785
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
785
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.1K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

586
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
586

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Astrocyte activation in the ventrolateral medulla modulates breathing and arousal states.

Nature communications·2026
Same author

Leukocyte-endothelial interactions and brain capillary function in neurological diseases.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

Real-time single-vessel analysis reveals vascular-type-dependent blood-brain barrier dysfunction in rodent models of status epilepticus and neuroinflammation.

Neurophotonics·2025
Same author

Glioma-associated microglia potentiate neuronal hyper-excitability in the glioma environment.

Neuro-oncology·2025
Same author

Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder.

Signal transduction and targeted therapy·2025
Same author

The role of medullary astrocytes in breathing and arousal: insights into glial regulation of respiratory function.

Research square·2025

Related Experiment Video

Updated: Jan 6, 2026

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.5K

C1q neutralization during epileptogenesis attenuates complement-mediated synaptic elimination and epileptiform

Yoonyi Jeong1,2,3, Hyun-Kyoung Lim2,4, Hayeon Kim1,2

  • 1Department of Biomedical Engineering, Sungkyunkwan University, Suwon, Republic of Korea.

Epilepsia
|October 21, 2025
PubMed
Summary

Blocking C1q complement signaling in epilepsy prevents synaptic loss and reduces brain hyperexcitability. This study shows C1q inhibition offers therapeutic benefits by preserving neuronal integrity and decreasing seizure activity.

Keywords:
C1qdendritic spinesepileptogenesismicrogliaphagocytosis

More Related Videos

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.5K
A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

12.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.5K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.5K
A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

12.7K

Area of Science:

  • Neuroscience
  • Immunology
  • Epilepsy Research

Background:

  • Aberrant C1q-C3 complement signaling in microglia and astrocytes contributes to synaptic dysfunction and neuronal loss in epilepsy.
  • C1q-mediated synaptic dysfunction disrupts neuronal circuitry and can lead to network hyperexcitability.

Purpose of the Study:

  • To investigate the therapeutic potential of C1q inhibition in preventing synaptic loss and attenuating epileptiform activity.
  • To determine if blocking C1q-driven pathways at critical times is effective in a mouse model of epilepsy.

Main Methods:

  • Examined microglial C1q and astrocytic C3 expression in mouse hippocampus post-pilocarpine-induced status epilepticus (SE).
  • Administered C1q-neutralizing antibody or control IgG at 7 days post-SE.
  • Assessed glial reactivity, dendritic spine density, and epileptiform activity via immunostaining, Golgi staining, and EEG.

Main Results:

  • C1q expression increased in the subacute phase, and astrocytic C3 expression increased and persisted chronically.
  • C1q antibody treatment at 7 days post-SE reduced microglial synaptic phagocytosis and astrocytic C3 activation.
  • Intervention preserved dendritic spine density and decreased interictal spike frequency in chronic EEG recordings.

Conclusions:

  • C1q is an upstream mediator of complement-driven neuronal loss during epileptogenesis.
  • C1q blockade interrupts microglial engulfment and astrocytic C3 upregulation, preserving synaptic integrity and reducing epileptiform activity.
  • C1q inhibition shows therapeutic potential for mitigating neuroinflammation, improving synaptic integrity, and reducing seizures in epilepsy.